Hematopoietic cell transplantation - specific comorbidity index (HCT-CI)

About

The Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was developed to identify relevant comorbidities in the allogeneic stem cell transplantation population and to enable risk assessment before allogeneic transplant. Data were collected retrospectively from 1055 patients undergoing nonablative (n=294) and ablative (n=761) conditioning prior to stem cell transplantation. Median age of the group was 45 and myeloid malignancies constituted the majority of diagnoses (66%). The investigators identified relevant comorbidities and derived a scoring system that predicted for 2-year non-relapse mortality post transplantation, after adjusting for age, disease risk, and conditioning regimen. The HCT-CI is able to classify patients into three risk groups: low risk (non-relapse mortality 14% at 2-years), intermediate risk (non-relapse mortality 21% at 2-years) and high risk (non-relapse mortality 41% at 2-years). The authors caution that other major pretransplant factors, including age and disease stage, should be considered when determining risk for allogeneic transplant.

References

Mohamed L Sorror, Michael B Maris, Rainer Storb, Frederic Baron, Brenda M Sandmaier, David G Maloney, Barry Storer

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Blood 2005 October 15, 106 (8): 2912-9

Created by on 28/12/2015

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.

1. Arrhythmia?

More Information

Arrhythmia Defined as: Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias

0/15 completed